The life and times of a GSK patent

Carl Battle has a big job on his hands managing pharmaceutical giant GlaxoSmithKline’s patent team. Michael Loney talks to him and some of his staff about bringing Anoro Ellipta to market, the dreaded patent cliff, combating generic drug companies and navigating developing countries’ IP hostility

GlaxoSmithKline (GSK) received an early Christmas present in December last year: the US Food and Drug Administration approved its new treatment for patients with chronic obstructive pulmonary disease (COPD). GSK has high hopes for Anoro Ellipta, a product that Thomson...